On 16 October, Stryker announced a definitive agreement to acquire Surpass Medical. This privately-held company develops next-generation flow diversion stent technology to treat brain aneurysms using a unique mesh design and delivery system.
Surpass’ key product, the NeuroEndoGraft family of flow diverters, is designed to redirect blood flow away from an aneurysm, allowing a stable clot to be formed within the aneurysm pouch. The NeuroEndoGraft is CE marked with a limited launch underway outside the USA. In addition, the company will begin enrolling patients in an investigational device exemption clinical trial in the fourth quarter of 2012.
“The acquisition of Surpass Medical further builds on Stryker’s global platform in the fast growing and highly innovative neurovascular market and helps broaden our offering in complete stroke care,” said Kevin A Lobo, president and CEO, Stryker. “We remain committed to furthering care in the interventional neurovascular space by offering patients and caregivers differentiated products that improve outcomes and help save lives.”
The transaction is expected to close in the fourth quarter of 2012.
